The effect of azoximer bromide (Polyoxidonium(®)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

A clinical need for aetiotropic coronavirus disease (COVID-19) treatments is required. The immune modulator azoximer bromide (AZB; Polyoxidonium(®)) is indicated in Russia for use against acute viral infections and during remission. In this study, adults hospitalized with COVID-19 (n=32) received AZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Efimov, Sergey V, Matsiyeuskaya, Natallia V, Boytsova, Olga V, Akhieva, Lyudmila Yu, Kvasova, Elena I, Harrison, Francisco, Karpova, Yulia S, Tikhonov, Anton, Khomyakova, Nadezhda F, Hardman, Tim, Rossi, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007208/
https://www.ncbi.nlm.nih.gov/pubmed/33828607
http://dx.doi.org/10.7573/dic.2020-11-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007208/
https://www.ncbi.nlm.nih.gov/pubmed/33828607
http://dx.doi.org/10.7573/dic.2020-11-1

Ejemplares similares